制药公司Rubicon Research 与Sebi的IPO档案为1,085 克罗尔。 Pharma firm Rubicon Research files Rs 1,085 crore IPO with Sebi.
制药公司Rubicon研究档案,与Sebi合作,为1,085 crore IPO提供。 Pharma firm Rubicon Research files for Rs 1,085 crore IPO with Sebi. 价值500卢比的新发行品和价值585卢比的新发行品,由Singapore Atlantic General RR Pte有限公司促销。 Fresh issue worth Rs 500 crore and OFS valued at Rs 585 crore by promoter, General Atlantic Singapore RR Pte Ltd. 用于偿还债务、购置、战略举措和一般公司目的的收益。 Proceeds to be used for debt repayment, acquisitions, strategic initiatives, and general corporate purposes. Rubicon在印度有两家受美国食品和食品管理局检查的研发设施和两家制造厂,共有69种美国食品和食品管理局核准的产品,46种处于不同的开发阶段。 Rubicon has two USFDA-inspected R&D facilities and two manufacturing units in India, with a portfolio of 69 USFDA-approved products and 46 in various stages of development.